Description
11992-1-AP targets Angiotensinogen/AGT in WB, IHC, IF/ICC, FC (Intra), IP, CoIP, ELISA applications and shows reactivity with human samples.
Tested Applications
Positive WB detected in: HuH-7 cells, HepG2 cells, human plasma
Positive IP detected in: human plasma
Positive IHC detected in: human liver tissueNote: suggested antigen retrieval withTE buffer pH 9.0;(*) Alternatively, antigen retrieval may be performed withcitrate buffer pH 6.0
Positive IF/ICC detected in: HeLa cells
Positive FC (Intra) detected in: HepG2 cells
Recommended dilution
Western Blot (WB): WB : 1:1000-1:4000
Immunoprecipitation (IP): IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
Immunohistochemistry (IHC): IHC : 1:50-1:500
Immunofluorescence (IF)/ICC: IF/ICC : 1:50-1:500
Flow Cytometry (FC) (INTRA): FC (INTRA) : 0.25 ug per 10^6 cells in a 100 µl suspension
Background Information
Angiotensinogen is a precursor of angiotensin II (Ang II), is expressed and synthesized largely in the liver and is cleaved by the enzyme renin in response to lowered blood pressure. It has a key role in mediating vascular constriction and regulating salt and fluid homeostasis. The resulting product, angiotensin I, is then cleaved by angiotensin converting enzyme (ACE) to generate the physiologically active enzyme angiotensin II. Mutations in this gene are associated with susceptibility to essential hypertension, and can cause renal tubular dysgenesis, a severe disorder of renal tubular development. Defects in this gene also have been associated with non-familial structural atrial fibrillation, and inflammatory bowel disease.